Angiography-proven liver metastases explain low efficacy of lymph node dissections in medullary thyroid cancer patients

European Journal of Surgical Oncology

Volumn 31, Issue 2, 2005, Pages 183-190

  Szavcsur, P ^a   Godeny M ^a   Bajzik, G ^b   Lengyel, E ^a   Repa, I ^b   Tron L ^c,d   Boer A ^a   Vincze, B ^a   Poti Z ^e   Szabolcs, I ^f   Esik O ^a,g  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^b SZENT ISTVÁN UNIVERSITY   (Hungary)

^c UNIVERSITY OF DEBRECEN   (Hungary)

^d INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^e UZSOKI HOSPITAL   (Hungary)

^f National Health Service Center   (Hungary)

^g SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Angiography; Liver metastases; Lymph node dissection; Medullary thyroid carcinoma

Indexed keywords

CALCITONIN;

ARTICLE; CANCER STAGING; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DIARRHEA; FOLLOW UP; HUMAN; IMAGING SYSTEM; INTERMETHOD COMPARISON; LIVER ANGIOGRAPHY; LIVER METASTASIS; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; THYROID MEDULLARY CARCINOMA;

ANGIOGRAPHY; BRAIN STEM NEOPLASMS; CALCITONIN; CERVIX UTERI; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; MALE; MEDIASTINUM; NEOPLASMS, BONE TISSUE; THYROID NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 13444252975     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2004.06.011     Document Type: Article

References (53)

1. N. Beressi J.M. Campos J.P. Beressi B. Franc P. Niccoli-Sire B. Conte-Devolx et al. Sporadic medullary microcarcinoma of the thyroid: A retrospective analysis of eighty cases Thyroid 8 1998 1039-1044
2. O. Gimm J. Ukkat H. Dralle Determinative factors of biochemical cure after primary and reoperative surgery for sporadic medullary thyroid carcinoma World J Surg 22 1998 562-568
3. H. Dralle I. Damm G.F.W. Scheumann J. Kotzerke E. Kupsch H. Geerlings et al. Compartment-oriented microdissection of regional lymph nodes in medullary thyroid carcinoma Surg Today 24 1994 112-121
4. H. Dralle G.F.W. Scheumann C. Proye F. Bacourt A. Frilling F. Limbert et al. The value of lymph node dissection in hereditary medullary thyroid carcinoma: A retrospective, European, multicentre study J Intern Med 238 1995 357-361
5. F. Kallinowski H.J. Buhr H. Meybier M. Eberhardt C. Herfarth Medullary carcinoma of the thyroid - therapeutic strategy derived from fifteen years of experience Surgery 114 1993 491-496
6. H.J. Buhr F. Kallinowski F. Raue K. Frank-Raue C. Herfarth Microsurgical neck dissection for metastasizing medullary thyroid carcinoma Eur J Surg Oncol 21 1995 195-197
7. D.D. Chi J.F. Moley Medullary thyroid carcinoma: Genetic advances, treatment recommendations, and the approach to the patient with persistent hypercalcitoninemia Surg Oncol Clin N Am 7 1998 681-706
8. D.L. Fraker M. Skarulis V. LiVolsi Thyroid tumors In: V. DeVita Jr. S. Hellman S.A. Rosenberg (Eds.) Cancer: Principles and practice of oncology 2001 Lippincott-Williams and Wilkins Philadelphia 1740-1763
9. E. Modigliani B. Franc P. Niccoli-Sire Diagnosis and treatment of medullary thyroid cancer Bailliere's Best Pract Res Clin Endocrinol Metab 14 2000 631-649
10. G.W. Randolph D. Maniar Medullary carcinoma of the thyroid Cancer Control 7 2000 253-261
11. N. Abdelmoumene M. Schlumberger P. Gardet A. Roche J.P. Travagli C. Francese et al. Selective venous sampling catheterisation for localisation of persisting medullary thyroid carcinoma Br J Cancer 69 1994 1141-1144
12. M.A. Block C.E. Jackson A.H. Tashjian Jr. Management of occult medullary thyroid carcinoma: Evidence only by serum calcitonin level elevations after apparently adequate neck operations Arch Surg 113 1978 368-372
13. J.D.I. Ellenhorn J.P. Shah M.F. Brennan Impact of therapeutic regional lymph node dissection for medullary carcinoma of the thyroid gland Surgery 114 1993 1078-1082
14. K. Frank-Raue F. Raue H.J. Buhr G. Baldauf D. Lorenz R. Ziegler Localization of occult persisting medullary thyroid carcinoma before microsurgical reoperation: High sensitivity of selective venous catheterization Thyroid 2 1992 113-117
15. J.F. Moley W.G. Dilley M.K. DeBenedetti Improved results of cervical reoperation for medullary thyroid carcinoma Ann Surg 225 1997 734-743
16. J.A. Norton J.L. Doppman M.F. Brennan Localization and resection of clinically inapparent medullary carcinoma of the thyroid Surgery 87 1980 616-622
17. L-E. Tisell G. Hansson S. Jansson H. Salander Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma Surgery 99 1986 60-66
18. J.A. Van Heerden C.S. Grant H. Gharib I.D. Hay D.M. Ilstrup Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma Ann Surg 212 1990 395-401
19. H.R. Alexander R.T. Jensen Pancreatic endocrine tumors In: V. DeVita Jr. S. Hellman S.A. Rosenberg (Eds.) Cancer: Principles and practice of oncology 2nd ed. 2001 Lippincott-Williams and Wilkins Philadelphia 1788-1813
20. S. Dominguez A. Denys Y. Menu P. Ruszniewski Hepatic arterial chemoembolization in the management of advanced digestive endocrine tumours Ital J Gastroenterol Hepatol 2 Suppl. 1999 S213-S215
21. R.T. Jensen G.M. Doherty Carcinoid tumors and the carcinoid syndrome In: V. DeVita Jr. S. Hellman (Eds.) Cancer: Principles and practice of oncology 6th ed. 2001 Lippincott Philadelphia 1813-1833
22. J.H. Oliver III R.L. Baron M.P. Federle B.C. Jones R. Sheng Hypervascular liver metastases: Do unenhanced and hepatic arterial phase CT images affect tumor detection? Radiology 205 1997 709-715
23. E.K. Paulson V.G. McDermott M.T. Keogan D.M. DeLong M.G. Frederick R.C. Nelson Carcinoid metastases to the liver: Role of triple-phase helical CT Radiology 206 1998 143-150
24. P. Soyer S.C. de Givry C. Gueye S. Lenormand E. Somveille A. Scherrer Detection of focal hepatic lesions with MR imaging: Prospective comparison of T2-weighted fast spin-echo with and without fat suppression, T2-weighted breath-hold fast spin-echo, and gadolinium chelate-enhanced 3D gradient-recalled imaging Am J Roentgenol 166 1996 1115-1121
25. B.E. Van Beers B. Gallez J. Pringot Contrast-enhanced MR imaging of the liver Radiology 203 1997 297-306
26. H.C. Weber D.J. Venzon J-T. Lin V.A. Fishbein M. Orbuch D.B. Strader et al. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome (ZES): A prospective long-term study Gastroenterology 108 1995 1637-1649
27. C.G. Moertel Karnofsky memorial lecture. An Odyssey in the land of small tumors J Clin Oncol 5 1987 1502-1522
28. 99mTc-MIBI imaging in the follow-up of patients with medullary carcinoma of the thyroid Eur J Nucl Med 23 1996 1367-1371
29. S. Adams R.P. Baum A. Hertel P.M. Schumm-Draeger K-H. Usadel G. Hör Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findings Eur J Nucl Med 25 1998 1277-1283
30. N. Arslan S. Ilgan D. Yuksel M. Serdengecti N. Bulakbasi Uǧur Ö. et al. Comparison of In-111 octreotide and Tc-99m (V) DMSA scintigraphy in the detection of medullary thyroid tumor foci in patients with elevated levels of tumor markers after surgery Clin Nucl Med 26 2001 683-688
31. D.L. Learoyd P.J. Roach G.M. Briggs L.W. Delbridge E.G. Wilmshurst B.G. Robinson Technetium-99m-sestamibi scanning in recurrent medullary thyroid carcinoma J Nucl Med 38 1997 227-230
32. L. Troncone V. Rufini P. Montemaggi F.M. Danza A. Lasorella R. Mastrangelo The diagnostic and therapeutic utility of radioiodinated metaiodobenzylguanidine (MIBG). 5 years of experience Eur J Nucl Med 16 1990 325-335
33. 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma J Nucl Med 43 2002 66-71
34. E. Baudin J. Lumbroso M. Schlumberger J. Leclere F. Giammarile P. Gardet et al. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma J Nucl Med 37 1996 912-916
35. T.M. Behr S. Gratz P.M. Markus R.M. Dunn M. Hufner A. Schauer et al. Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: Are carcinoembryonic antigen and somatostatin receptor expression prognostic factors? Cancer 80 1997 2436-2457
36. L. Berna A. Chico X. Matias-Guiu E. Mato A. Catafau C. Alonso et al. Use of somatostatin analogue scintigraphy in the localization of recurrent medullary thyroid carcinoma Eur J Nucl Med 25 1998 1482-1488
37. U. Dörr M-L. Sautter-Bihl H. Bihl The contribution of somatostatin receptor scintigraphy to the diagnosis of recurrent medullary carcinoma of the thyroid Semin Oncol 21 1994 42-45
38. K. Frank-Raue H. Bihl U. Dörr H. Buhr R. Ziegler F. Raue Somatostatin receptor imaging in persistent medullary thyroid carcinoma Clin Endocrinol 42 1995 31-37
39. D.J. Kwekkeboom J.C. Reubi S.W.J. Lamberts H.A. Bruining A.H. Mulder H.Y. Oei et al. In vivo somatostatin receptor imaging in medullary thyroid carcinoma J Clin Endocrinol Metab 76 1993 1413-1417
40. L. Manil F. Boudet P. Motte P. Gardet J.C. Saccavini J.D. Lumbroso et al. Positive anticalcitonin immunoscintigraphy in patients with medullary thyroid carcinoma Cancer Res 49 1989 5480-5485
41. J. Barbet P. Peltier S. Bardet J.P. Vuillez I. Bachelot S. Denet et al. Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA X anti-DTPA-indium bispecific antibody J Nucl Med 39 1998 1172-1178
42. K. Brandt-Mainz S.P. Müller R. Görges B. Saller A. Bockisch The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer Eur J Nucl Med 27 2000 490-496
43. P. Gasparoni D. Rubello G. Ferlin Potential role of fluorine-18-deoxyglucose (FDG) positron emission tomography (PET) in the staging of primitive and recurrent medullary thyroid carcinoma J Endocrinol Invest 20 1997 527-530
44. T.J. Musholt P.B. Musholt F. Dehdashti J.F. Moley Evaluation of fluorodeoxyglucose-positron emission tomographic scanning and its association with glucose transporter expression in medullary thyroid carcinoma and pheochromocytoma: A clinical and molecular study Surgery 122 1997 1049-1060 discussion 1060-1061
45. M. Diehl J.H. Risse K. Brandt-Mainz M. Dietlein K.H. Bohuslavizki P. Matheja et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: Results of a multicentre study Eur J Nucl Med 28 2001 1671-1676
46. M.D. Ben Mrad P. Gardet A. Roche P. Rougier C. Calmettes P. Motte et al Value of venous catheterization and calcitonin studies in the treatment and management of clinically inapparent medullary thyroid carcinoma Cancer 63 1989 133-138
47. G.W. Sizemore Medullary carcinoma of the thyroid gland Semin Oncol 14 1987 306-314
48. K.M. Gautvik K. Talle B. Hager O.G. Jørgensen M. Aas Early liver metastases in patients with medullary carcinoma of the thyroid gland Cancer 63 1989 175-180
49. T.J. Babineau W.D. Lewis R.L. Jenkins R. Bleday G.J. Steele Jr R.A. Forse Role of staging laparoscopy in the treatment of hepatic malignancy Am J Surg 167 1994 151-155
50. W.S. Tung T.M. Vesely J.F. Moley Laparoscopic detection of hepatic metastases in patients with residual or recurrent medullary thyroid cancer Surgery 118 1995 1024-1030
51. C.J.M. Lips Clinical management of the multiple endocrine neoplasia syndromes: Results of a computerized opinion poll at the Sixth International Workshop on Multiple Endocrine Neoplasia and von Hippel-Lindau disease J Intern Med 243 1998 589-594
52. S. Schröder W. Böcker H. Baisch C.G. Burk H. Arps I. Meiners et al. Prognostic factors in medullary thyroid carcinomas. Survival in relation to age, sex, stage, histology, immunocytochemistry, and DNA content Cancer 61 1988 806-816
53. L. Scopsi G. Sampietro P. Boracchi R. Del Bo M. Gullo M. Placucci et al. Multivariate analysis of prognostic factors in sporadic medullary carcinoma of the thyroid. A retrospective study of 109 consecutive patients Cancer 78 1996 2173-2183